Subtopic Deep Dive
Familial Amyloid Polyneuropathy Treatment
Research Guide
What is Familial Amyloid Polyneuropathy Treatment?
Familial Amyloid Polyneuropathy (FAP) treatment targets hereditary transthyretin (hATTR) amyloidosis with polyneuropathy using TTR stabilizers, RNAi therapeutics like patisiran and inotersen, and liver transplantation to halt neuropathy progression.
Patisiran, an RNAi therapeutic, improved clinical manifestations in the APOLLO trial (Adams et al., 2018, 2745 citations). Inotersen enhanced neurologic disease course and quality of life despite thrombocytopenia risks (Benson et al., 2018, 1352 citations). Pharmacokinetic studies confirm patisiran's efficacy in reducing TTR production (Zhang et al., 2019, 196 citations). Over 10 key papers since 2017 focus on these interventions.
Why It Matters
Patisiran halts peripheral and autonomic neuropathy progression, improving quality of life in hATTR-PN patients (Adams et al., 2018). Inotersen treatment slows neurologic decline, enabling better management of polyneuropathy symptoms with monitoring for renal and platelet toxicities (Benson et al., 2018). These therapies extend survival and reduce disability in rare genetic disease, impacting clinical guidelines for early intervention (Luigetti et al., 2020). Real-world application includes genetic screening for V122I variants in at-risk populations (Damrauer et al., 2019).
Key Research Challenges
Thrombocytopenia Risk Management
Inotersen causes thrombocytopenia and glomerulonephritis, requiring enhanced monitoring (Benson et al., 2018). Balancing efficacy against hematologic toxicities challenges long-term use. Clinical protocols demand frequent blood tests to mitigate risks.
Heterogeneous Disease Progression
hATTR amyloidosis varies by mutation, complicating uniform treatment response assessment (Kristen et al., 2018). Polyneuropathy and cardiac involvement progress differently across patients. Standardized endpoints like mNIS+7 score help but need refinement (Adams et al., 2017).
Access and Delivery Barriers
RNAi therapies like patisiran require subcutaneous infusion every 3 weeks, limiting accessibility (Zhang et al., 2019). High costs and specialized centers restrict global use. Pharmacokinetic optimization aims to improve subcutaneous delivery (Zhang et al., 2019).
Essential Papers
Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis
David Adams, Alejandra González‐Duarte, William O’Riordan et al. · 2018 · New England Journal of Medicine · 2.7K citations
In this trial, patisiran improved multiple clinical manifestations of hereditary transthyretin amyloidosis. (Funded by Alnylam Pharmaceuticals; APOLLO ClinicalTrials.gov number, NCT01960348 .).
Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis
Merrill D. Benson, Márcia Waddington‐Cruz, John L. Berk et al. · 2018 · New England Journal of Medicine · 1.4K citations
Inotersen improved the course of neurologic disease and quality of life in patients with hereditary transthyretin amyloidosis. Thrombocytopenia and glomerulonephritis were managed with enhanced mon...
Patisiran, an RNAi Therapeutic for the Treatment of Hereditary Transthyretin-Mediated Amyloidosis
Arnt V. Kristen, Senda Ajroud‐Driss, Isabel Conceição et al. · 2018 · Neurodegenerative Disease Management · 254 citations
Hereditary transthyretin-mediated amyloidosis is a rapidly progressive, heterogeneous disease caused by the accumulation of misfolded transthyretin protein as amyloid fibrils at multiple sites, and...
A Review of Patisiran (ONPATTRO®) for the Treatment of Polyneuropathy in People with Hereditary Transthyretin Amyloidosis
Ivan Urits, Daniel Swanson, Michael C. Swett et al. · 2020 · Neurology and Therapy · 222 citations
Pharmacokinetics of Patisiran, the First Approved RNA Interference Therapy in Patients With Hereditary Transthyretin‐Mediated Amyloidosis
Xiaoping Zhang, Varun Goel, Gabriel J. Robbie · 2019 · The Journal of Clinical Pharmacology · 196 citations
Abstract Hereditary transthyretin‐mediated (hATTR) amyloidosis is a rare, inherited, progressively debilitating, and often fatal disease caused by deposition of mutated transthyretin (TTR) protein....
Trial design and rationale for APOLLO, a Phase 3, placebo-controlled study of patisiran in patients with hereditary ATTR amyloidosis with polyneuropathy
David Adams, Ole B. Suhr, P. James B. Dyck et al. · 2017 · BMC Neurology · 170 citations
This trial is registered at clinicaltrials.gov ( NCT01960348 ); October 9, 2013.
Association of the V122I Hereditary Transthyretin Amyloidosis Genetic Variant With Heart Failure Among Individuals of African or Hispanic/Latino Ancestry
Scott M. Damrauer, Kumardeep Chaudhary, Judy H. Cho et al. · 2019 · JAMA · 150 citations
Among individuals of African or Hispanic/Latino ancestry enrolled in 2 academic medical center-based biobanks, the TTR V122I genetic variant was significantly associated with heart failure.
Reading Guide
Foundational Papers
No pre-2015 foundational papers available; start with Adams et al. (2018) APOLLO trial for patisiran efficacy baseline and Benson et al. (2018) for inotersen, as they establish RCT evidence for RNAi therapies.
Recent Advances
Zhang et al. (2019) on patisiran pharmacokinetics; Luigetti et al. (2020) on diagnosis-treatment integration; Ioannou et al. (2023) on heart failure therapies in ATTR context.
Core Methods
RNAi (patisiran lipid nanoparticle silencing), antisense oligonucleotides (inotersen), mNIS+7 scoring for neuropathy, TTR level quantification via pharmacokinetics (Adams et al., 2018; Zhang et al., 2019).
How PapersFlow Helps You Research Familial Amyloid Polyneuropathy Treatment
Discover & Search
Research Agent uses searchPapers and exaSearch to find patisiran trials like Adams et al. (2018), then citationGraph reveals 2745 citing works on hATTR-PN outcomes. findSimilarPapers links to Benson et al. (2018) inotersen study for comparative RNAi therapies.
Analyze & Verify
Analysis Agent applies readPaperContent to extract APOLLO trial endpoints from Adams et al. (2018), verifies claims with CoVe against Benson et al. (2018), and runs PythonAnalysis on mNIS+7 progression data for statistical significance (p<0.001). GRADE grading scores high-quality RCT evidence from these NEJM papers.
Synthesize & Write
Synthesis Agent detects gaps in long-term patisiran data post-APOLLO (Adams et al., 2018), flags contradictions in cardiac vs. neuropathy outcomes. Writing Agent uses latexEditText, latexSyncCitations for trial comparisons, and latexCompile to generate formatted reviews with exportMermaid for treatment workflow diagrams.
Use Cases
"Extract and plot mNIS+7 score changes from patisiran APOLLO trial vs. placebo."
Research Agent → searchPapers('Adams 2018 patisiran') → Analysis Agent → readPaperContent → runPythonAnalysis(pandas plot of progression data) → matplotlib graph of neuropathy halt (p<0.001 improvement).
"Draft a review comparing patisiran and inotersen for hATTR-PN with citations."
Synthesis Agent → gap detection → Writing Agent → latexEditText('compare Adams 2018 Benson 2018') → latexSyncCitations → latexCompile → PDF with structured therapy table and synced NEJM refs.
"Find GitHub repos analyzing patisiran pharmacokinetic models."
Research Agent → searchPapers('Zhang 2019 patisiran pharmacokinetics') → paperExtractUrls → paperFindGithubRepo → githubRepoInspect → code for TTR reduction simulations from Zhang et al. exposure-response data.
Automated Workflows
Deep Research workflow conducts systematic review: searchPapers(50+ hATTR papers) → citationGraph → GRADE all RCTs like Adams (2018) → structured report on FAP outcomes. DeepScan applies 7-step analysis with CoVe checkpoints to verify inotersen safety data from Benson (2018). Theorizer generates hypotheses on combining patisiran with liver transplant from trial endpoints (Adams et al., 2017).
Frequently Asked Questions
What is Familial Amyloid Polyneuropathy treatment?
FAP treatment uses RNAi agents like patisiran and inotersen to silence mutant TTR genes, stabilizing protein and halting polyneuropathy (Adams et al., 2018; Benson et al., 2018).
What are main treatment methods?
Key methods include patisiran (subcutaneous RNAi, APOLLO trial), inotersen (antisense oligonucleotide), with monitoring for thrombocytopenia; liver transplant reduces mutant TTR (Adams et al., 2018; Benson et al., 2018).
What are key papers?
Adams et al. (2018, NEJM, 2745 citations) on patisiran; Benson et al. (2018, NEJM, 1352 citations) on inotersen; Zhang et al. (2019) on patisiran pharmacokinetics (196 citations).
What are open problems?
Challenges include managing inotersen toxicities, addressing disease heterogeneity across mutations, and improving therapy access for non-cardiac hATTR-PN (Benson et al., 2018; Kristen et al., 2018).
Research Amyloidosis: Diagnosis, Treatment, Outcomes with AI
PapersFlow provides specialized AI tools for Biochemistry, Genetics and Molecular Biology researchers. Here are the most relevant for this topic:
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Paper Summarizer
Get structured summaries of any paper in seconds
Deep Research Reports
Multi-source evidence synthesis with counter-evidence
See how researchers in Life Sciences use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Familial Amyloid Polyneuropathy Treatment with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Biochemistry, Genetics and Molecular Biology researchers